Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- Community Cancer Institute — Clovis, California
- PIH Health Whittier Hospital — Downey, California
- Compassionate Cancer Care Medical Group - Inc — Fountain Valley, California
- Los Angeles Cancer Network — Los Angeles, California
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in California: - Research Site — Duarte, California
- Research Site — Fountain Valley, California
- Research Site — Greenbrae, California
- Research Site — Irvine, California
- Research Site — La Jolla, California
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in California: - Community Cancer Institute — Clovis, California
- City of Hope — Duarte, California
- Marin Cancer Care — Greenbrae, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine — Irvine, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in California: - Ventura County Hematology Oncology Specialists — Camarillo, California
- Los Angeles Cancer Network - (Admin Only / Central IDS) - No Patients — Glendale, California
- Los Angeles Cancer Network - Good Samaritan — Los Angeles, California
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California
- Rolling Oaks Radiology - Oxnard — Oxnard, California
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- Onco Inst of Hope and Innovation — Cerritos, California
- City of Hope National Medical — Duarte, California
- Providence Medical Foundation — Fullerton, California
- Palo Alto Medical Foundation — Mountain View, California
Phase 3 Recruiting Industry
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…
Sponsor: AstraZeneca
NCT ID: NCT04862663
Sites in California: - Research Site — Fountain Valley, California
- Research Site — Glendale, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Napa, California
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in California: - Clinical Trial Site — Fountain Valley, California
- Clinical Trial Site — Glendale, California
- Clinical Trial Site — La Jolla, California
- Clinical Trial Site — Los Alamitos, California
- Clinical Trial Site — Los Angeles, California
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center — Fullerton, California
- City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California San Diego - Moores Cancer Center — La Jolla, California
- University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in California: - Research Site — La Jolla, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — San Luis Obispo, California
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in California: - Clinical Trial Site — Beverly Hills, California
- Clinical Trial Site — Santa Barbara, California
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in California: - University Of California - San Diego Moores Cancer Center — La Jolla, California
- Cedar Sinai - Samuel Oschin Cancer Center — Los Angeles, California
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center — Palo Alto, California
Phase 3 Recruiting Academic/Other
This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after chemother…
Sponsor: City of Hope Medical Center
NCT ID: NCT06763328
Sites in California: - City of Hope Medical Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California-Riverside — Riverside, California
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in California: - PCR Oncology — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Epic Care-Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in California: - OPN Healthcare (Arcadia Location) — Arcadia, California
- City of Hope National Medical Center — Duarte, California
- Glendale Adventist — Glendale, California
- OPN Healthcare (Los Alamitos Location) — Los Alamitos, California
- Cedars Sinai — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in California: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- LA Cancer Network — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Industry
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Sponsor: Criterium, Inc.
NCT ID: NCT04567420
Sites in California: - USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in California: - City of Hope — Duarte, California
- City of Hope — Huntington Beach, California
- City of Hope — Irvine, California
- City of Hope — Long Beach, California
- University of California, San Francisco — San Francisco, California
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in California: - City of Hope — Duarte, California
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen recepto…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428396
Sites in California: - Cedars Sinai Medical Center ( Site 0012) — Beverly Hills, California
- Moores Cancer Center at UC San Diego Health ( Site 0025) — La Jolla, California
- USC/Norris Comprehensive Cancer Center ( Site 0013) — Los Angeles, California
- USC Norris Oncology Hematology Newport Beach ( Site 0029) — Newport Beach, California
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in California: - Avenzo Therapeutics Recruiting Site — Los Angeles, California
- Avenzo Therapeutics Recruiting Site — Los Angeles, California